Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $1.05 as of March 11^th. CHRS’s trailing P/E was 4.20 according to Yahoo Finance.

[caption id="attachment_1205754" align="aligncenter" width="768"] A researcher in a lab holding a bispecific antibody, illustrating the leading edge of cancer treatments.[/caption]

Coherus BioSciences (CHRS) recently reported its Q4 and full-year 2024 earnings, with the primary focus...